Commodore Capital LP Mereo Biopharma Group PLC Transaction History

Commodore Capital LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.33 - $1.69 $645,140 - $3.3 Million	-1,954,970 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$1.51 - $2.59 $27,161 - $46,588	-17,988 Reduced 0.91%	1,954,970 $3.13 Million
Q3 2021 Nov 15, 2021	SELL	$2.2 - $3.17 $190,896 - $275,064	-86,771 Reduced 4.21%	1,972,958 $4.78 Million
Q2 2021 Aug 16, 2021	BUY	$2.94 - $4.08 $32,257 - $44,765	10,972 Added 0.54%	2,059,729 $6.53 Million
Q1 2021 May 17, 2021	BUY	$2.6 - $4.43 $505,645 - $861,541	194,479 Added 10.49%	2,048,757 $6.9 Million
Q4 2020 Feb 16, 2021	BUY	$1.95 - $3.6 $3.62 Million - $6.68 Million	1,854,278 New	1,854,278 $6.64 Million

107M

209K

479K

Ticker MREO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,986,000
Market Cap $431M
Description
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...

Get notified when there are updates to the investment portfolio of Commodore Capital LP, based on Form 13F filings with the SEC.

Stay updated on Commodore Capital LP with notifications on news.